A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation

NCT02112045 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

90

Enrollment

OTHER

Sponsor class

Stopped Terminated due to results of interim analysis

Conditions

Multiple Myeloma

Interventions

DRUG: Granix
DRUG: High dose melphalan (HDR)
PROCEDURE: Autologous Stem Cell Transplant (ASCT)

Sponsor

Washington University School of Medicine